Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma

Cancer Science

Volumn 99, Issue 8, 2008, Pages 1643-1649

  Kohga, Keisuke ^a   Takehara, Tetsuo ^a   Tatsumi, Tomohide ^a   Ohkawa, Kazuyoshi ^a   Miyagi, Takuya ^a   Hiramatsu, Naoki ^a   Kanto, Tatsuya ^a   Kasugai, Tsutomu ^b   Katayama, Kazuhiro ^b   Kato, Michio ^c   Hayashi, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER TISSUE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; TUMOR IMMUNITY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHRONIC DISEASE; EMBOLIZATION, THERAPEUTIC; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; UP-REGULATION;

EID: 49749111514     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00859.x     Document Type: Article

References (21)

1. Bauer S, Groh V, Wu J et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-9.
2. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived γδT cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879-84.
3. Jinushi M, Takehara T, Tatsumi T et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 2003; 104: 354-61.
4. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004; 114: 560-8.
5. Raffaghello L, Prigione I, Airoldi I et al. Downregulation and/or release of NKG2D ligands as an immune evasion strategy of human neuroblastoma. Neoplasia 2004; 6: 558-68.
6. Ogasawara K, Lanier LL. NKG2D in NK and T cell-mediated immunity. J Clin Immunol 2005; 25: 534-40.
7. Caudert JD, Held W. The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol 2006; 16: 333-43.
8. Groh V, Wu J, Yee C, Spies T. Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-8.
9. Salih HR, Rammensee HG, Steinle A. Downregulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169: 4098-102.
10. Salih HR, Antropius H, Gieseke F et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102: 1389-96.
11. Mincheva-Nilsson L, Nagaeva O, Chen T et al. Placenta-derived soluble MHC class I chain-related molecules down-regulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: A possible novel immune escape mechanism for fetal survival. J Immunol 2006; 176: 3585-92.
12. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. Int J Cancer 2006; 118: 684-7.
13. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih RH. Soluble MICB in malignant diseases: Analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother 2006; 55: 1584-9.
14. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004; 127: S35-50.
15. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004; 127: S5-16.
16. Takayasu K, Arii S, Ikai I et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-9.
17. Jinushi M, Takehara T, Tatsumi T et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 2005; 43: 1013-20.
18. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
19. Borchers MT, Harris NL, Wesselkamper SC, Vitucci M, Cosman D. NKG2D ligands are expressed on stressed human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006; 291: L222-31.
20. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436: 1186-90.
21. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor. Cancer Res 2006; 66: 2520-6.